Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2015

View Archived Issues

New RNAi drug using extrahepatic delivery platform shows promise for metastatic ccRCC

Targeting retinal VEGR receptors, a promising strategy for retinal angiogenesis disorders

Malaria protein targets toxins to cancer cells

Grifols opens Bioscience Division global operations facility in Ireland

ABT-126 shows antidyskinetic effects in animal models

CDRD and viDA Therapeutics partner to discover treatments for DLE

Roche reports third quarter 2015 progress

Vasculotide, a potential treatment of Alzheimer's disease

TRPV1 and TRPA1 activation reduces muscular cramps

Acalabrutinib receives U.S. orphan designation for Waldenstrom macroglobulinemia

Auris Medical and King's College London to collaborate on small-molecule tinnitus therapy

FDA grants deflazacort orphan drug designation for pediatric juvenile idiopathic arthritis

Ares Trading patents novel INF-beta protein analogues

Amakem presents LIMK-1 and/or LIMK-2 inhibitors

Merck & Co. discloses TrKA inhibitors

Emory University develops AEP inhibitors

Arrowhead describes targeted RNAi therapeutics for HBV, renal cell carcinoma, cardiovascular disease

XOMA starts phase II trial of XOMA-358 in patients with congenital hyperinsulinism

Aeglea BioTherapeutics doses first patient in phase I study of AEB-1102 for solid tumors

Mast Therapeutics begins phase II study of vepoloxamer for chronic heart failure

RedHill Biopharma reports topline results from phase I trial of Yeliva

CHMP recommends extension of approval of rilpivirine to adolescents with HIV infection

Phase I trial of ISIS-GSK4-LRx triggers milestone payment to Isis Pharmaceuticals

Pembrolizumab superior to docetaxel in overall survival of patients with advanced NSCLC

MMP-12 inhibitors described in recent Bayer Schering Pharma patents

Bristol-Myers Squibb reports HIV maturation inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...